

# Michigan Firm Rolls out Due Diligence Package to Help Drug Inventors, Makers Get to Market

ANN ARBOR, Mich., Oct 08, 2008 (BUSINESS WIRE) -- Michigan Technology and Research Institute (MITRI) today announced the launch of "D4 Resources," an expanded and comprehensive Drug Development Due Diligence service.

D4 Resources will provide expert assessments of drug candidates to venture capital groups, new pharmaceutical companies, biotechnology companies and inventors.

Dr. Felix de la Iglesia, a founder of MITRI with a staff of over 100 years of combined pharmaceutical experience, announced the new service product by MITRI.

According to de la Iglesia, D4 Resources offers an integrated single point focus and strategy for determining the medical and commercialization potential for bio tech products and small molecule entities from early drug candidate optimization through clinical proof-of-concept and registration.

"We believe this is a natural progression of integrating D4 Resources into the services we provide to the scientific and capital investment community," de la Iglesia said. "It will allow us to better service our clients while ensuring key safety and efficacy considerations are addressed."

Founded in 2007, the MITRI principal scientists have broad experience in assessing drug candidates, both from within major pharmaceutical companies and obtaining novel intellectual property as a basis for a new company. This dual perspective ensures a clear focus on drug development milestones and meeting patient therapeutic needs while ensuring the best utilization of capital support.

"Our emphasis with D4 Resources is to provide a cost effective and personal alternative to pharmaceutical groups by identifying a compound's assets and liabilities and then to provide strategic options," added Dr. Elizabeth Garofalo, a founder and MITRI Technical Center president.

## About MITRI

MITRI is a privately held integrated pharmaceutical expediting organization with expert consulting capabilities, as well as genetic testing and biomarker laboratories. The Institute is designed to improve decision making and optimize pharmaceutical development strategies that allow identification of high-potential drug molecules. MITRI provides tools, ideas, and laboratory support to help clients pick the most promising new drug candidates and focus on their potential as new patient therapies. The MITRI services can compliment a company's existing capabilities or handle all aspects of drug development. MITRI provides specific options, including strategic program opportunities, testing protocols, assembly of research and global registration documentation, pathology peer review and study logistics.

Additional information is available at [www.MTRIInstitute.com](http://www.MTRIInstitute.com) or by calling 734-222-0010.

SOURCE: Michigan Technology & Research Institute LLC